Daily Derm Times: May 5, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD

Christopher Bunick, MD, PhD, discusses the evolving role of OX40-targeted biologics in atopic dermatitis treatment ahead of the upcoming RAD conference.

Peter Lio, MD, Advocates for Personalized Pediatric Dermatology

Peter Lio, MD, discusses innovative treatments for pediatric atopic dermatitis, including microbiome therapies and botanical options.

Off-Label Ixekizumab is Effective for HS After Treatment Failure with Adalimumab

Ixekizumab shows promise in restoring clinical response for hidradenitis suppurativa patients previously unresponsive to adalimumab, highlighting new treatment options.

Gearing Up for RAD Insights From Summer Conferences

Explore vital insights on melanoma awareness, skin cancer disparities, and atopic dermatitis management in the latest issue of Dermatology Times.

Nonadherence Remains Common Concern in Dermatology

Researchers conducted a review of adherence behaviors for patients with dermatological diseases and provided an update on management strategies.

The State of Melanoma Care: Advances, Access, and the Road Ahead

This Melanoma Monday, we take a look at melanoma care in the US, from treatments to persistent gaps in access, early detection, and long-term outcomes.